SecBot SecBot
DEFA14A ·Filed May 26, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001193125-26-239481
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the June 4, 2026 annual meeting vote outcome for Ms. Szela's re-election. A significant 'against' vote would signal governance concerns, but the board's proactive supplement suggests they expect close scrutiny rather than defeat. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.24
T+0 close · May 26, 2026 · via day close
Latest settled
+14.36%
T+60 · $11.71
Vs SPY
+12.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $10.24entry
  2. T+1 · 6mo ago −2.64%α −3.19% · $9.97
  3. T+5 · 6mo ago −15.48%α −15.95% · $8.66
  4. T+20 · 5mo ago +1.17%α +3.07% · $10.36
  5. T+60 · 3mo ago +14.36%α +12.48% · $11.71

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee Mary T. Szela, who serves on four public company boards. The board argues her experience and attendance record justify her re-election and notes her intention to reduce board seats before the 2027 annual meeting. The filing is routine proxy solicitation material with no financial impact.

Key Financial Metrics

Vote
director election
Meeting
2026-06-04
Seats Contested
1

Key Facts

  • Supplement to the definitive proxy statement dated April 10, 2026, for the annual meeting on June 4, 2026.
  • Board unanimously recommends voting FOR the election of Mary T. Szela to a three-year term expiring at the 2029 annual meeting.
  • Ms. Szela serves as CEO/President of TriSalus Life Sciences and on the boards of Kura, TriSalus, Absci Corporation, and Averin Capital Acquisition Corp.
  • Ms. Szela attended over 85% of Kura board/committee meetings in 2025 and over 90% since joining the board in November 2018.
  • Ms. Szela has expressed intention to step down from one other public company board seat before Kura's 2027 proxy statement filing.
  • All four public companies on which Ms. Szela serves are non-accelerated filers; three are life sciences companies.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • Potential negative vote from proxy advisors or institutional investors due to overboarding concerns.
  • If Ms. Szela fails to reduce board commitments as promised, governance issues could resurface at the 2027 annual meeting.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-239481
Document: 0001193125-26-239481-index-headers.html0001193125-26-239481
Document: 0001193125-26-239481-index.html0001193125-26-239481
Document: 0001193125-26-239481.txt0001193125-26-239481

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026